| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Alkermes plc$51.94
-1.84 (-3.42%)
B 60Pipeline Score Fair Value Pharma · Commercial
Market Cap
6.89 B
EPS
0.93
P/E Ratio
45.94 $
Value Trade
85.05 M
SEC Financials
Q1 2026Dilution Risk
Revenue
392.91 M
R&D Expenses
103.34 M
Operating CF
-165.74 M
Total Assets
4.26 B
Total Liabilities
2.51 B
Equity
1.75 B
D/E Ratio
12,345
-3.79 %
Week
9.79 %
1 Month
15.72 %
3 Month
30.96 %
6 Month
67.27 %
5 Year
569.09 %
All Time
Cash Data
Cash Position
511.86 M
Monthly Burn
55.25 M
Runway
7.3 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
1.69 M
52 Week Range
25.17 - 42.83
% held by Insiders
2.21 %
% held by Institutions
107.49 %
Enterprise Value
7.96 B
Total Shares
165.05 M
Short %
10.75 %
Float Shares
162.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alkermes plc
347Total events
11Upcoming
131Tier-1 (high impact)
2017 – 2033Coverage
Upcoming catalysts 11
Event history 336
Jun 17, 2026
▲Oral PresentationalixorextonPresentation
Detailed positive results from Vibrance-2 Phase 2 study presented at SLEEP 2026
Narcolepsy Type 2source ↗
Jun 15, 2026
Jun 3, 2026
●Oral PresentationPresentation
Alkermes to participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 21, 2026
◆Oral PresentationPresentation
Data presentations at Spring 2026 scientific conferences
psychiatrysource ↗
May 12, 2026
▲Topline ReadoutLUMRYZApprovedClinical Data
Positive topline results from REVITALYZ Phase 3 study of LUMRYZ in idiopathic hypersomnia
idiopathic hypersomniasource ↗
May 12, 2026
▲Primary Endpoint MetLUMRYZApprovedClinical Data
Primary endpoint met: ESS improvement vs placebo (p<0.0001)
idiopathic hypersomniasource ↗
Apr 16, 2026
◆Oral PresentationalixorextonPresentation
Additional data from Vibrance-1 Phase 2 study of Alixorexton to be presented at AAN 2026
Narcolepsy Type 1source ↗
Apr 14, 2026
◆PublicationLybalviApprovedPresentation
Long-term analysis of LYBALVI effects on negative symptoms published in The Journal of Clinical Psychiatry
schizophreniasource ↗
Apr 1, 2026
▲Trial InitiationalixorextonTrial
Initiation of Phase 3 Brilliance NT1 Study 304
narcolepsy type 1source ↗
Q2 2026
◆Topline ReadoutLUMRYZApprovedClinical Data
Data expected from REVITALYZ LUMRYZ idiopathic hypersomnia phase 3 study
idiopathic hypersomniasource ↗
Drug Pipeline Intelligence
B60
Pipeline Score $3.6B
Pipeline ValueFair Value
Valuation Signal23
Drugs Scored1.7x
rNPV / MCap Top 88%
Small Cap (rank 110 of 911)
Percentile RankAlkermes plc holds a solid B-grade pipeline (60/100), with $7.4B risk-adjusted pipeline value, led by ALKS 5461 in Major Depressive Disorder (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKS 5461 Small molecule | Major Depressive Disorder | Phase 3 | NCT01381107 | 49% | $1.3B | COMPLETED | 3,242 | - | - | Jul 1, 2011 | - | Aug 23, 2011 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LUMRYZ | idiopathic hypersomnia | Phase 3 | 2026-05-12 | ESS: p<0.0001; PGI C: p<0.0001; IHSS: p<0.0001 | Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Alkermes Announces Positive Topline Results From REVITALYZ SM Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Ext Read More | |
LUMRYZ | idiopathic hypersomnia | Phase 3 | 2026-05-12 | ESS: p<0.0001; PGI C: p<0.0001; IHSS: p<0.0001 | Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Alkermes Announces Positive Topline Results From REVITALYZ SM Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Ext Read More | |
LUMRYZ | idiopathic hypersomnia | Phase 3 | 2026-05-12 | ESS: p<0.0001; PGI C: p<0.0001; IHSS: p<0.0001 | Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Alkermes Announces Positive Topline Results From REVITALYZ SM Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Ext Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALKS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALKS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALKSAlkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes has reported positive findings from the Vibrance-2 Phase 2 study of Alixorexton, targeting adults with Narcolepsy Type 2. The results were showcased at the SLEEP 2026 conference, highlighting the potential of Alixorexton as a treatment option. This development marks a significant step forward in addressing Narcolepsy Type 2.
Read more →ALKSAlkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Alkermes has announced that Alixorexton has received orphan drug designations in both the U.S. and Europe. This designation is intended to facilitate the development of the drug for rare diseases. The announcement highlights Alkermes' commitment to addressing unmet medical needs in these regions.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe DUBLIN
Alkermes plc announced that their investigational drug alixorexton has received orphan drug designations from the FDA and the European Commission for treating narcolepsy and idiopathic hypersomnia. This designation underscores the drug's potential benefits in addressing unmet medical needs for patients with these rare neurological conditions. The company is advancing its clinical development with ongoing phase 3 and phase 2 studies, emphasizing optimism for the drug's future in the market.
Read more →ALKSAlkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Alkermes is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. The event will provide a platform for the company to discuss its strategies and developments in the biopharma sector. Further details about the conference and Alkermes' involvement have not been disclosed.
Read more →ALKSAlkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Alkermes is set to present new data at the American Society of Clinical Psychopharmacology Annual Meeting, highlighting its leadership in psychiatry and orexin biology. This event will showcase the company's advancements and contributions to the field. Details regarding the specific data to be presented were not disclosed in the article.
Read more →ALKSAlkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
Alkermes presented data from its psychiatry portfolio and sleep research at scientific conferences in Spring 2026. The focus was on real-world patient experiences, highlighting the company's commitment to understanding patient needs and outcomes in these therapeutic areas. The event showcased the latest findings and advancements in their research efforts.
Read more →ALKS▲ +8%on this news
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Alkermes Announces Positive Topline Results From REVITALYZ SM Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Ext
Alkermes plc announced positive topline results from the Phase 3 REVITALYZ study evaluating LUMRYZ (sodium oxybate) in adults with idiopathic hypersomnia. The study showed statistically significant and clinically meaningful improvements in excessive daytime sleepiness, meeting all primary and key secondary endpoints. The results suggest LUMRYZ could serve as an effective treatment for this patient population, which lacks adequate therapy options. Alkermes plans to file a supplemental New Drug Application with the FDA following these positive outcomes.
Read more →ALKS▲ +8%on this news
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Alkermes has announced positive topline results from its REVITALYZ Phase 3 study, which evaluated LUMRYZ (sodium oxybate) extended-release in adults with idiopathic hypersomnia. The study's findings suggest that LUMRYZ may be an effective treatment option for this condition, potentially enhancing the quality of life for affected individuals.
Read more →ALKS▲ +6.1%on this news
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2026 Financial Results — First Quarter Revenues of $392.9 Million; GAAP Net
Alkermes plc has reported its financial results for the first quarter of 2026, revealing revenues of $392.9 million despite a GAAP net loss of $66.5 million. The company successfully completed the acquisition of Avadel Pharmaceuticals, which is expected to bolster its entry into the sleep medicine market. Additionally, Alkermes has initiated a Phase 3 clinical program for alixorexton, affirming its commitment to advancing treatments for narcolepsy. While the adjusted EBITDA has shown improvement, significant operating losses suggest challenges remain.
Read more →ALKS▲ +6.1%on this news
Alkermes plc Reports First Quarter 2026 Financial Results
Alkermes plc has reported its financial results for the first quarter of 2026. The article does not provide specific details about the financial performance or any significant developments during this period. Further analysis may be required to understand the implications of these results on the company's future.
Read more →ALKSAlkermes to Report First Quarter Financial Results on May 5, 2026
Alkermes plc will host a conference call on May 5, 2026, to discuss its first quarter financial results. The event will be accessible via a webcast and phone call for both U.S. and international participants. The company, focused on neuroscience, has a diverse portfolio and an active pipeline of clinical candidates.
Read more →ALKSAlkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Alkermes will present additional data from the Vibrance-1 Phase 2 study of Alixorexton, focusing on its effects in patients with Narcolepsy Type 1. This presentation is scheduled for the American Academy of Neurology (AAN) 2026 Annual Meeting. The details of the findings have not been disclosed yet.
Read more →ALKSFindings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
The article discusses findings from a long-term analysis of LYBALVI® (olanzapine and samidorphan) and its effects on negative symptoms of schizophrenia. The study was published in The Journal of Clinical Psychiatry. Specific details about the findings or implications are not provided in the text.
Read more →ALKSAlkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Alkermes has launched the Brilliance Studies, a Phase 3 program to evaluate alixorexton for narcolepsy types 1 and 2. The studies will assess the drug's safety and efficacy compared to placebo over 12 weeks. With promising results from earlier trials, the company aims to optimize dosing and efficacy for patients suffering from narcolepsy.
Read more →ALKS▼ -7%on this news
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
Alkermes plc has announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting strong performance. The company also shared its financial expectations for 2026 during a conference call. Alkermes focuses on developing innovative treatments in neuroscience, with a diverse pipeline of clinical candidates.
Read more →ALKS▼ -7%on this newsshared move
Alkermes plc Announces CEO Succession Plan
Alkermes plc announced the retirement of CEO Richard Pops, effective July 31, 2026, with Blair Jackson set to succeed him on August 1, 2026. Pops will remain as Chairman and advisor. Under Pops' leadership, Alkermes has grown significantly, focusing on neuroscience drug development and expanding its portfolio, including a recent acquisition of Avadel Pharmaceuticals.
Read more →ALKS▼ -7%on this newsshared move
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
Alkermes plc announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2, 2026. The management will engage in a fireside chat at 9:10 a.m. ET, which will be available via live webcast. The company is known for its innovative medicines in neuroscience and has a robust pipeline.
Read more →ALKS▼ -7%on this newsshared move
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Announces CEO Succession Plan — Richard Pops to Retire from Role of Chief Executive Officer Follow
Alkermes plc has announced that Richard Pops will retire as CEO effective July 31, 2026, after a notable 35-year tenure. Blair Jackson, currently the Executive Vice President and COO, has been appointed as the new CEO, effective August 1, 2026. Under Pops' leadership, Alkermes has evolved significantly, now employing over 2,000 individuals and achieving substantial annual revenues. The transition comes as the company continues to pursue innovations in neuroscience, highlighted by the recent acquisition of Avadel Pharmaceuticals and ongoing development of therapeutic candidates.
Read more →ALKSAlkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Alkermes plc has completed its acquisition of Avadel Pharmaceuticals, gaining access to Avadel's FDA-approved product, LUMRYZ, which treats narcolepsy. This strategic acquisition accelerates Alkermes' entry into the sleep medicine market and enhances its commercial capabilities. The deal is expected to be financially beneficial by 2026, although it involves significant debt financing.
Read more →ALKSAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
Alkermes plc will host a conference call on February 25, 2026, to discuss its fourth quarter and year-end financial results for 2025. The management will also outline financial expectations for 2026 and provide updates on the company's operations. The event will be accessible via a webcast and conference call.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - Augm
Alkermes plc has completed the acquisition of Avadel Pharmaceuticals, which will allow it to enter the sleep medicine market more aggressively. Adding Avadel's FDA-approved LUMRYZ product will diversify Alkermes' commercial portfolio and potentially enhance its revenue growth. The transaction was executed under Irish law and includes financing through a combination of cash and borrowed funds. Alkermes expects this acquisition to bolster its strategic position in treating sleep disorders, leveraging Avadel's existing commercial capabilities.
Read more →ALKSForward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, i
Alkermes is poised for significant growth in the neuroscience sector, driven by its promising alixorexton candidate for narcolepsy, which recently received FDA Breakthrough Therapy designation. The company plans to initiate a registrational phase 3 program for alixorexton in early 2026, following positive results from earlier studies. Additionally, the acquisition of Avadel Pharmaceuticals is expected to augment Alkermes' revenue growth and market position. However, the company acknowledges the inherent risks and uncertainties associated with its forward-looking statements regarding future performance and development timelines.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 DUBLIN
Alkermes plc announced that the U.S. FDA has granted Breakthrough Therapy designation to its investigational drug, alixorexton, for treating narcolepsy type 1. This designation is based on positive phase 1 and 2 clinical data, including significant improvements in wakefulness noted in the Vibrance-1 phase 2 study. The company aims to begin the global phase 3 program for alixorexton in early 2026, highlighting its potential as a new standard of care for narcolepsy type 1.
Read more →ALKSAlkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
Alkermes plc has announced an increased offer to acquire Avadel Pharmaceuticals plc, valuing the latter at up to $2.37 billion. The offer includes $21.00 in cash per share and a contingent value right contingent upon FDA approval of Avadel's LUMRYZ by the end of 2028. This new offer follows an unsolicited proposal from H. Lundbeck A/S, which was considered a superior offer initially, but Avadel's board has since decided that the terms of Alkermes' proposal are more favorable. The acquisition is anticipated to close in the first quarter of 2026, pending necessary conditions.
Read more →ALKSUPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
Alkermes has made a revised bid of $21 per share for Avadel Pharmaceuticals, surpassing Lundbeck's offer. This bid includes a one-time contingent value right of $1.50, contingent on FDA approval of Avadel's narcolepsy drug, Lumyrz. The deal, valued at approximately $2.37 billion, has been accepted by both companies' boards and is expected to close in Q1 2026.
Read more →ALKSAlkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached...
Alkermes plc has announced an increased offer to acquire Avadel Pharmaceuticals plc for up to $22.50 per share. This includes $21.00 in cash and a contingent value right for an additional $1.50, dependent on FDA approval for Avadel's LUMRYZ™ product. The acquisition, valued at approximately $2.37 billion, has been approved by both companies' boards and is expected to close in Q1 2026, pending regulatory conditions.
Read more →ALKS▼ -6.4%on this newsshared move
Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
Lundbeck has made an unsolicited bid of approximately $2.42 billion for Avadel Pharmaceuticals, surpassing Alkermes' previous offer of $2.1 billion. The deal could increase in value based on sales milestones of Avadel's narcolepsy drugs. Avadel's stock has risen significantly, but negotiations with Alkermes are still ongoing. This bidding war follows another recent acquisition in the biotech sector.
Read more →ALKS▼ -6.4%on this newsshared move
Alkermes Response to Avadel Announcement Alkermes plc ("Alkermes") (Nasdaq: ALKS) notes the announcement made by Avadel Pharmaceuticals plc ("Avadel") regarding a possible offer by H....
Alkermes plc has acknowledged Avadel Pharmaceuticals' announcement about a potential acquisition offer from H. Lundbeck A/S. The Alkermes board is currently evaluating its options in light of this development, as stipulated in their existing Transaction Agreement with Avadel. Further updates will be provided as necessary.
Read more →ALKSAlkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
Alkermes' alixorexton has demonstrated promising results in a Phase II study for narcolepsy type 2, meeting key endpoints related to wakefulness and daytime sleepiness. Analysts have deemed these results highly competitive, paving the way for Phase III trials expected to start in early 2026. The drug is also being tested for other sleep disorders, enhancing its market potential.
Read more →ALKS▼ -7.1%on this newsshared move
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 – Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2,...
Alkermes announced positive topline results from the Vibrance-2 Phase 2 study of alixorexton, an oral orexin 2 receptor agonist for narcolepsy type 2. The study met its dual primary endpoints, showing significant improvements in wakefulness and excessive daytime sleepiness compared to placebo. Alixorexton was well tolerated, with no serious adverse events reported, paving the way for a Phase 3 program.
Read more →ALKS▼ -7.1%on this newsshared move
Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients W
Alkermes announced positive topline results from its Vibrance-2 Phase 2 study of alixorexton, an oral orexin 2 receptor agonist. The study showed statistically significant and clinically meaningful improvements in wakefulness and excessive daytime sleepiness in patients with narcolepsy type 2. Alixorexton was generally well tolerated, and results from this study will inform future Phase 3 development. The findings mark an important milestone for the treatment of narcolepsy and indicate potential for this new therapeutic option.
Read more →ALKSAlkermes to Participate in Two Upcoming Investor Conferences Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference...
Alkermes plc has announced its participation in two upcoming investor conferences: the Stifel 2025 Healthcare Conference on November 13, 2025, and the Jefferies Global Healthcare Conference in London on November 19, 2025. The live webcasts will be accessible on their website and archived for 14 days. Alkermes focuses on developing innovative medicines in neuroscience.
Read more →ALKSFORM 8.1(a) & (b) (Opening Position Disclosure) Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997,...
Alkermes plc has disclosed its opening position in relation to a takeover offer for Avadel Pharmaceuticals plc, as required by the Irish Takeover Panel. The disclosure includes details about interests and short positions held by Alkermes and its financial advisors. The company confirms it is the offeror in this transaction.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2025 Financial Results — Third Quarter Revenues of $394.2 Million — &
Alkermes plc has reported its financial results for the third quarter of 2025, achieving revenues of $394.2 million and raising its financial expectations for the year. The company experienced strong revenue growth, particularly in its commercial product portfolio. Additionally, it has made significant progress in its orexin 2 receptor agonist program for narcolepsy, with positive data presented from a phase 2 study. However, GAAP net income showed a decline compared to the previous year, highlighting some challenges alongside its growth.
Read more →ALKSAlkermes plc Reports Third Quarter 2025 Financial Results Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving ...
Alkermes plc reported strong financial results for Q3 2025, with revenues of $394.2 million and a net income of $82.8 million. The company raised its financial outlook for the year, attributing growth to robust demand across its product portfolio. Additionally, progress was made in its development pipeline, particularly with the orexin 2 receptor agonist program for narcolepsy. The company is preparing to initiate a phase 3 clinical program for alixorexton in early 2026.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, I
Alkermes plc has announced a definitive agreement to acquire Avadel Pharmaceuticals plc for up to $20.00 per share, valuing Avadel at approximately $2.1 billion. This acquisition, expected to close in the first quarter of 2026, will enhance Alkermes' portfolio with LUMRYZ, an FDA-approved treatment for narcolepsy. The transaction is projected to be immediately accretive and leverages Alkermes' existing commercial capabilities, while providing new avenues for growth in the sleep medicine market. The deal has already received approval from the boards of both companies and requires further regulatory and shareholder approvals.
Read more →ALKSAlkermes to Report Third Quarter Financial Results on October 28, 2025 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to...
Alkermes plc will host a conference call on October 28, 2025, to discuss its third quarter financial results. The call will be accessible via a dedicated phone line and webcast, with a replay available shortly after the event. Alkermes is focused on developing treatments for various neurological disorders.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 249 8927 Alkermes Appoints Joshua Reed as Chief Financial Officer DUBLIN
Alkermes has appointed Joshua Reed as the new Chief Financial Officer, effective September 15, 2025. Reed has over three decades of financial expertise, particularly in the biopharmaceutical sector, having previously served as CFO at Omega Therapeutics and Aldeyra Therapeutics. He will report to CEO Richard Pops and join the management committee to help advance Alkermes's strategic financial goals. The leadership expresses confidence in Reed's ability to enhance company performance and shareholder value.
Read more →ALKSAlkermes Appoints Joshua Reed as Chief Financial Officer Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. ...
Alkermes plc has appointed Joshua Reed as its new Chief Financial Officer, effective September 15, 2025. Reed, who has over 30 years of experience in financial leadership within the biotechnology sector, will report to CEO Richard Pops. His extensive background includes previous CFO roles at Omega Therapeutics and Aldeyra Therapeutics, as well as significant experience at Bristol Myers Squibb.
Read more →ALKSAlkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on...
Alkermes plc has announced the launch of its 8th Annual Alkermes Pathways Research Awards program, which will accept applications from September 15 to December 15, 2025. The program aims to support early-career researchers focusing on schizophrenia, bipolar I disorder, and associated sleep disturbances. Grants of up to $100,000 will be awarded to eligible applicants, evaluated by an independent committee.
Read more →ALKSAlkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with...
Alkermes plc announced positive results from the Vibrance-1 Phase 2 study of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1. The study demonstrated significant improvements in wakefulness, cognition, and fatigue over six weeks, with alixorexton being well tolerated. The company plans to advance alixorexton into Phase 3 trials in early 2026.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcole
Alkermes has reported positive results from the Vibrance-1 Phase 2 study of alixorexton, a novel orexin 2 receptor agonist for treating narcolepsy type 1. The study involved 92 patients and demonstrated significant improvements in wakefulness, cognition, and fatigue with a favorable safety profile. Alixorexton was well tolerated across all doses tested, and the company plans to initiate a global Phase 3 program in early 2026, indicating a commitment to further development of this promising treatment.
Read more →ALKSAlkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 Alkermes plc (Nasdaq: ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients...
Alkermes plc announced the presentation of detailed results from its Vibrance-1 phase 2 study on alixorexton for narcolepsy type 1 at the World Sleep Congress 2025. The study demonstrated positive efficacy and safety outcomes, with three oral presentations scheduled to discuss the findings. The company will also host an investor webcast to share insights on the study results.
Read more →ALKSAlkermes plc Reports Second Quarter 2025 Financial Results Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance...
Alkermes plc reported strong financial results for Q2 2025, with revenues of $390.7 million and a GAAP net income of $87.1 million. The company highlighted positive topline results from its Vibrance-1 study of alixorexton for narcolepsy type 1. Alkermes reiterated its financial expectations for 2025 and plans to present detailed results at the World Sleep Congress.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2025 Financial Results — Second Quarter Revenues of $390.7 Million —
Alkermes plc reported its second quarter financial results for 2025, highlighting revenues of $390.7 million and a GAAP net income of $87.1 million. The company has reiterated its financial expectations for the year and noted positive topline results from the Vibrance-1 trial of alixorexton in narcolepsy type 1. The results from proprietary products showed strong growth compared to last year, but total revenues dropped compared to the prior year. The company is set to present detailed study results at the upcoming World Sleep Congress.
Read more →ALKS▼ -8.8%on this news
Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients W
Alkermes announced positive topline results from the Vibrance-1 Phase 2 study, showing that alixorexton significantly improved wakefulness in patients with narcolepsy type 1 compared to placebo. The study found that all tested doses of alixorexton led to meaningful enhancements in various patient-reported outcomes, such as fatigue and cognition. The treatment was generally well tolerated, with no serious adverse events. These favorable results support Alkermes' plans to advance alixorexton into Phase 3 development.
Read more →ALKS▼ -8.8%on this news
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 – Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in ...
Alkermes announced positive topline results from the Vibrance-1 Phase 2 study of alixorexton in patients with narcolepsy type 1. The study demonstrated significant improvements in wakefulness and patient-reported outcomes related to fatigue and cognition. Alixorexton was well tolerated, with no serious adverse events reported. The results support moving forward to a global Phase 3 program.
Read more →ALKSAlkermes to Report Second Quarter Financial Results on July 29, 2025 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss ...
Alkermes plc will host a conference call on July 29, 2025, to discuss its second quarter financial results. The event will be accessible via a webcast and a dedicated phone line for participants. The company is recognized for its innovative medicines in neuroscience and has a strong pipeline for neurological disorders.
Read more →ALKSAlkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations...
Alkermes plc announced the presentation of research at several key scientific conferences this spring, focusing on its psychiatry products LYBALVI and ARISTADA. The presentations included analyses of safety, tolerability, and treatment effects, particularly related to schizophrenia and bipolar I disorder. These events coincided with Mental Health Awareness Month, emphasizing the importance of mental health support.
Read more →ALKSAlkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global...
Alkermes plc announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference, scheduled for June 9, 2025. The management will engage in a fireside chat presentation, which will be available via live webcast and archived for 14 days. This event underscores Alkermes' focus on investor relations and its portfolio in neuroscience.
Read more →ALKSAlkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 Alkermes plc (Nasdaq: ALKS) today announced plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the...
Alkermes plc announced plans to present new research on ALKS 2680 at SLEEP 2025, including eight posters and two oral presentations. The investigational drug, an orexin 2 receptor agonist, is in phase 2 development for narcolepsy and idiopathic hypersomnia. Key findings from prior studies indicate significant improvements in sleep latency and a favorable safety profile.
Read more →ALKS▲ +6.3%on this news
Alkermes plc Reports First Quarter 2025 Financial Results Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid ...
Alkermes plc reported its first quarter 2025 financial results, achieving revenues of $306.5 million and a GAAP net income of $22.5 million. The company reiterated its financial expectations for the year and highlighted progress in its ALKS 2680 program, with enrollment completed in phase 2 studies for narcolepsy. However, total revenues saw a decline compared to the previous year.
Read more →ALKS▲ +6.3%on this news
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2025 Financial Results — First Quarter Revenues of $306.5 Million — &
Alkermes plc reported its first quarter 2025 financial results, revealing revenues of $306.5 million and a GAAP net income of $22.5 million. The company reaffirmed its 2025 financial expectations and highlighted significant advancements in its clinical pipeline, particularly with the ALKS 2680 program for narcolepsy. While revenue and net income have decreased compared to the previous year, the completion of enrollment in key studies and expectations for future data releases are positive indicators for the company’s growth. However, challenges remain due to declining revenues and the formal separation of its oncology business.
Read more →ALKSNew Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand...
A recent survey by Alkermes, conducted by The Harris Poll, reveals insights into the diagnosis and treatment journey for individuals with Alcohol Use Disorder (AUD). The survey highlights that negative consequences often drive the decision to seek treatment, and that healthcare providers play a crucial role in this process. Despite the positive impacts of treatment, stigma remains a significant barrier for many individuals seeking help.
Read more →ALKSAlkermes to Report First Quarter Financial Results on May 1, 2025 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss...
Alkermes plc will host a conference call and webcast on May 1, 2025, to discuss its first quarter financial results. The event will begin at 8:00 a.m. ET and will be accessible via the company's website. A replay of the call will be available shortly after the event concludes.
Read more →ALKSAlkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in ...
Alkermes plc announced its participation in the 24th Annual Needham Virtual Healthcare Conference, where management will discuss the development of Orexin Receptor Agonists for sleep-wake disorders. The event is scheduled for April 9, 2025, and will be accessible via a live webcast. This participation highlights Alkermes' commitment to advancing treatments in neuroscience.
Read more →ALKSAlkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680...
Alkermes plc has initiated the Vibrance-3 Phase 2 clinical study to evaluate ALKS 2680 for idiopathic hypersomnia. This study will assess the drug's safety and efficacy compared to a placebo, involving approximately 96 participants across multiple countries. The primary endpoint focuses on reducing sleepiness, with secondary endpoints examining severity and adverse events.
Read more →ALKSNew National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder People living with schizophrenia or bipolar I disorder (BDI) often face long and complex diagnostic and treatment journeys. Results from a newly...
A recent survey conducted by The Harris Poll on behalf of Alkermes highlights the complex treatment journeys faced by patients with schizophrenia and bipolar I disorder. Healthcare providers emphasize the importance of medication adherence and quality of life, revealing that frequent medication switches can adversely affect patient experiences. The findings aim to inform better treatment strategies and improve patient outcomes.
Read more →ALKSAlkermes to Participate in Upcoming Investor Conferences Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen ...
Alkermes plc has announced its participation in two upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Management will engage in webcast fireside chats at these events, which will be accessible live and archived for later viewing. This initiative reflects Alkermes' commitment to investor relations and transparency.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended
Alkermes plc reported its financial results for 2024, highlighting a strong performance with total revenues of $1.56 billion, an 18% increase from the previous year. The company also reported a GAAP net income of $372 million, indicating robust financial health. Alkermes is progressing on several drug development projects, including ongoing phase 2 studies for ALKS 2680 in narcolepsy, with expected data release in the second half of 2025. The overall outlook for 2025 remains positive with significant revenue expectations for proprietary products.
Read more →ALKSAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for...
Alkermes plc reported its financial results for 2024, highlighting total revenues of $1.56 billion and an 18% increase in net sales of proprietary products. The company achieved a GAAP net income of $372 million, down from the previous year. Alkermes is advancing its development pipeline, particularly with ongoing Phase 2 studies for ALKS 2680 in narcolepsy, with data expected in the second half of 2025.
Read more →ALKSAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to...
Alkermes plc will host a conference call on February 12, 2025, to discuss its fourth quarter and year-end 2024 financial results. The management will also outline financial expectations for 2025 and provide updates on the company's operations. Investors can access the call via phone or webcast, with a replay available afterward.
Read more →ALKSAlkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd...
Alkermes plc announced that CEO Richard Pops will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will include a corporate overview and a question-and-answer session. Investors can access the live webcast on the company's website, which will be available for 14 days post-event.
Read more →ALKSAlkermes to Participate in Upcoming Investor Conferences Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx ...
Alkermes plc has announced its participation in two upcoming investor conferences, the 7th Annual Evercore ISI HealthCONx Conference and the Piper Sandler 36th Annual Healthcare Conference. The events will take place on December 3 and December 4, 2024, respectively. Live webcasts of the presentations will be available on the company's website.
Read more →ALKSAlkermes to Participate in Two Upcoming Investor Conferences Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference...
Alkermes plc announced its participation in two upcoming investor conferences, namely the Stifel Healthcare Conference on November 18, 2024, and the Jefferies London Healthcare Conference on November 19, 2024. Management will present at both events, which will be accessible via live webcasts. This initiative underscores the company's dedication to investor relations.
Read more →ALKSAlkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole ...
Alkermes plc presented new research findings at two key scientific conferences, highlighting the effectiveness of LYBALVI and ARISTADA in treating schizophrenia and bipolar I disorder. The studies showed significant reductions in healthcare resource utilization among patients following treatment initiation. Additionally, data on the investigational drug ALKS 2680 for narcolepsy was shared, showcasing the company's commitment to advancing neuroscience research.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2024 Financial Results — Third Quarter Revenues of $378.1 Million — &
Alkermes plc has reported its financial results for the third quarter of 2024, showcasing revenues of $378.1 million, which reflects a solid performance marked by an 18% increase in net sales of proprietary products. The company also highlighted strong GAAP net income from continuing operations, amounting to $92.8 million. Looking ahead, Alkermes is optimistic about the potential of its investigational drug ALKS 2680, especially with ongoing studies in narcolepsy. The firm has reiterated its financial expectations for 2024 and is preparing for a promising year in its business strategy.
Read more →ALKSAlkermes plc Reports Third Quarter 2024 Financial Results Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024. "Our third quarter financial results reflect strong...
Alkermes plc reported strong financial results for Q3 2024, with revenues of $378.1 million, reflecting an 18% increase in proprietary product sales year-over-year. The company reiterated its financial expectations for 2024, highlighting the potential of its investigational drug ALKS 2680 in treating narcolepsy. Alkermes aims to enhance shareholder value through strategic investments in its product pipeline.
Read more →ALKSAlkermes to Report Third Quarter Financial Results on October 24, 2024 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, Oct. 24, 2024 to...
Alkermes plc will host a conference call and webcast on October 24, 2024, to discuss its third quarter financial results. The event will begin at 8:00 a.m. ET and will be accessible via phone and online. A replay will be available shortly after the event concludes. Alkermes is focused on developing treatments for various neurological disorders.
Read more →ALKSForward-Looking Statements Note Regarding Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Li
Alkermes has presented forward-looking statements concerning its ALKS 2680, a treatment for narcolepsy and idiopathic hypersomnia. The company highlighted the potential therapeutic value of its orexin portfolio while acknowledging the inherent risks and uncertainties involved in drug development. ALKS 2680 is currently in Phase 2 clinical trials, and the strategy review indicates a focus on advancing their understanding of orexin mechanisms. Alkermes cautions investors not to place undue reliance on these projections as actual results may significantly differ.
Read more →ALKSAlkermes to Host Investor Event to Review Orexin Portfolio Strategy Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. ...
Alkermes plc will host an investor event on October 9, 2024, to discuss its orexin portfolio and development strategy. The event will include presentations from the R&D team and a panel discussion with clinicians. It will be accessible virtually, allowing broader participation from financial analysts and institutional investors.
Read more →ALKSAlkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2...
Alkermes plc announced that it will present positive clinical data from its phase 1b study of ALKS 2680 at Sleep Europe 2024. The study evaluated the drug in patients with narcolepsy type 2 and idiopathic hypersomnia, demonstrating improved wakefulness and good tolerability. The presentations will include both oral and poster formats, highlighting the drug's potential as a treatment option.
Read more →ALKSAlkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the TD Cowen 4th Annual Novel...
Alkermes plc will participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference on September 26, 2024. The management will engage in a fireside chat presentation, which will be accessible via a live webcast. This event highlights Alkermes' ongoing efforts in the neuroscience field and its innovative product pipeline.
Read more →ALKSAlkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on...
Alkermes plc has announced the launch of its 7th annual Pathways Research Awards program, which will accept applications from September 20 to November 30, 2024. This competitive grant program aims to support early-career researchers focusing on schizophrenia and bipolar disorder. Grants of up to $100,000 will be awarded to qualified applicants, contributing to advancements in neuroscience.
Read more →ALKSAlkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Morgan Stanley 22nd Annual Global ...
Alkermes plc will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. The management's fireside chat presentation is scheduled for 2:35 p.m. EDT. A live webcast will be available on the company's website and archived for 14 days for later access.
Read more →ALKSAlkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-2 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS...
Alkermes has initiated the Vibrance-2 Phase 2 study to evaluate ALKS 2680 for narcolepsy type 2. This randomized, double-blind trial will assess the safety and efficacy of the drug compared to placebo. Approximately 80 participants will be enrolled, with the primary endpoint focusing on sleepiness reduction. The study follows promising results from a Phase 1 trial.
Read more →ALKS▲ +6%on this news
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2024 Financial Results — Second Quarter Revenues of $399.1 Million —
Alkermes plc reported its second quarter 2024 financial results, highlighting total revenues of $399.1 million, up significantly from the previous year. The company saw a 16% year-over-year increase in net sales of proprietary products, underscored by a GAAP net income of $94.7 million. The firm reiterated its financial expectations for the year and expressed confidence in its operational priorities for advancing its neuroscience pipeline. Notably, Alkermes is progressing in its research efforts for treatments related to narcolepsy and other neurological disorders.
Read more →ALKS▲ +6%on this news
Alkermes plc Reports Second Quarter 2024 Financial Results Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2024. "Our second quarter results reflect solid execution...
Alkermes plc reported solid financial results for Q2 2024, with revenues of $399.1 million and a 16% increase in net sales of proprietary products. The company reaffirmed its financial expectations for the year and highlighted its operational focus on advancing its neuroscience development pipeline, particularly the phase 2 program for ALKS 2680 in narcolepsy. Despite a decrease in GAAP net income from continuing operations, Alkermes remains in a strong financial position.
Read more →ALKSAlkermes to Report Second Quarter Financial Results on July 24, 2024 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 24, 2024 to...
Alkermes plc will host a conference call and webcast on July 24, 2024, to discuss its second quarter financial results. The event will be accessible via the company's website, with a replay available shortly after. Alkermes focuses on developing innovative treatments for various neurological disorders.
Read more →ALKSAlkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating...
Alkermes plc presented promising data from a Phase 1b study of ALKS 2680, an investigational treatment for narcolepsy type 1, at SLEEP 2024. The study demonstrated statistically significant improvements in sleep latency and patient-reported alertness compared to placebo. ALKS 2680 was well tolerated, with no severe adverse events reported. The ongoing Vibrance-1 Phase 2 study will further evaluate its efficacy and safety.
Read more →ALKSAlkermes to Participate in Two Upcoming Investor Conferences Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences....
Alkermes plc has announced its participation in two upcoming investor conferences, including the Jefferies Healthcare Conference on June 6, 2024, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The events will feature management in fireside chat presentations, accessible via live webcasts. Alkermes focuses on developing innovative medicines for neurological disorders.
Read more →ALKSAlkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the...
Alkermes plc plans to present three posters related to ALKS 2680 at SLEEP 2024, including data from a Phase 1b study and the study design for the Phase 2 Vibrance-1 trial. The presentations will highlight safety and efficacy assessments for the investigational treatment for narcolepsy. Additionally, qualitative interviews with patients will shed light on the burden of narcolepsy.
Read more →ALKSAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and...
Alkermes plc announced the presentation of research related to its psychiatry products, LYBALVI and ARISTADA, at four prominent scientific conferences this spring. These presentations will highlight findings from long-term safety studies and healthcare resource utilization research, particularly focusing on patients with schizophrenia and bipolar I disorder. The events coincide with Mental Health Awareness Month, emphasizing the importance of mental health advocacy.
Read more →ALKSAlkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo...
Alkermes plc has finalized the sale of its Athlone, Ireland facility to Novo Nordisk for approximately $91 million. This sale is part of Alkermes' strategy to improve operational efficiency and align its infrastructure with business needs. The company will continue subcontracting certain activities at the facility until the end of 2025, and expects the transaction to enhance profitability.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2024 Financial Results — First Quarter Revenues of $350.4 Million — &
Alkermes plc reported its financial results for the first quarter of 2024, indicating a strong revenue growth of $350.4 million and a GAAP net income from continuing operations of $38.9 million. The company highlights positive prescription growth for LYBALVI and the advancement of its investigational drug ALKS 2680 for narcolepsy. With solid support for its strategic priorities, Alkermes reiterates its financial expectations for the year ahead. The company is also progressing with additional studies and initiatives within its neuroscience portfolio.
Read more →ALKSAlkermes plc Reports First Quarter 2024 Financial Results Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter...
Alkermes plc reported its first quarter 2024 financial results, showcasing a net income of $38.9 million and revenues of $350.4 million. The company highlighted strong prescription growth for LYBALVI and the advancement of ALKS 2680 in clinical trials for narcolepsy. Alkermes reiterated its financial expectations for the year, emphasizing its focus on neuroscience.
Read more →ALKSAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS...
Alkermes plc has initiated the Vibrance-1 Phase 2 study to evaluate ALKS 2680, an oral orexin 2 receptor agonist, for treating narcolepsy type 1. The trial will assess the safety and efficacy of ALKS 2680 compared to placebo over six weeks. Approximately 80 patients will participate, with the study aiming to measure changes in sleepiness and cataplexy rates.
Read more →ALKSAlkermes to Report First Quarter Financial Results on May 1, 2024 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss ...
Alkermes plc will hold a conference call and webcast on May 1, 2024, to discuss its first quarter financial results. The event will start at 8:00 a.m. ET and will be accessible via the company's website. A replay will be available shortly after the event concludes.
Read more →ALKSAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a...
Alkermes plc announced positive topline results from a Phase 1b study of ALKS 2680, an investigational orexin 2 receptor agonist for narcolepsy type 2 and idiopathic hypersomnia. The study demonstrated significant improvements in mean sleep latency compared to placebo across all doses tested. ALKS 2680 was well tolerated, with no serious adverse events reported, leading to plans for a Phase 2 study later in 2024.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy, +1 781 609 6419 Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness
Alkermes announced positive topline results from a Phase 1b study of ALKS 2680, an oral orexin 2 receptor agonist. The study showed statistically significant improvements in sleep latency for patients with narcolepsy type 2 and idiopathic hypersomnia compared to a placebo. ALKS 2680 was well tolerated, with mild treatment-emergent adverse events noted. The company plans to move forward with a Phase 2 study in the second half of 2024.
Read more →ALKSAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research...
Alkermes presented findings from a phase 3 study on LYBALVI at the 2024 Congress of the Schizophrenia International Research Society. The study evaluated the long-term safety and tolerability of LYBALVI in patients treated for up to four years. Results indicated sustained symptom control and minimal adverse effects, reinforcing the drug's potential as a maintenance therapy for schizophrenia and bipolar I disorder.
Read more →ALKSAlkermes Announces Appointment of Nancy S. Lurker to Board of Directors Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the...
Alkermes plc has appointed Nancy S. Lurker as an independent director on its Board. Lurker, a seasoned healthcare executive, brings significant experience in the pharmaceutical industry, which is expected to enhance the company's strategic growth. CEO Richard Pops emphasized the importance of her expertise in driving the company's portfolio expansion and innovative product launches.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors DUBLIN
Alkermes plc has appointed Nancy S. Lurker as an independent director to its Board of Directors. Lurker is recognized for her extensive leadership experience in the pharmaceutical industry, which includes key roles at EyePoint Pharmaceuticals and Novartis. The appointment aims to strengthen the Board's capabilities in alignment with the company's growth strategies. Richard Pops, CEO of Alkermes, emphasized the importance of her experience in driving company growth and advancing its portfolio of products.
Read more →ALKS▲ +16.3%on this news
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2023 and provided financial expectations for...
Alkermes plc reported strong financial results for 2023, with total revenues of $1.66 billion and a significant increase in net sales of proprietary products. The company anticipates a 30% EBITDA margin in 2024, driven by growth in its commercial products, including LYBALVI. However, it also noted a loss from discontinued operations and the upcoming expiration of certain royalties.
Read more →ALKSAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 15, 2024 to...
Alkermes plc will host a conference call on February 15, 2024, to discuss its fourth quarter and year-end financial results for 2023. The management will also outline financial expectations for 2024 and provide updates on the company's progress. Investors can access the call via phone or webcast.
Read more →ALKSAlkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd...
Alkermes plc announced that its CEO, Richard Pops, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will include a corporate overview and will be followed by a question and answer session. Investors can access the live webcast through Alkermes' website.
Read more →ALKSAlkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan) Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability...
Alkermes announced positive topline results from a phase 3 study of LYBALVI, showing long-term safety and efficacy in treating schizophrenia and bipolar I disorder. The study involved 523 participants, with a significant number completing four years of treatment. Results indicated stable symptom control and minimal adverse effects on weight and metabolic health.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 609 6806 Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk DUBLIN
Alkermes plc has announced a definitive agreement to sell its Athlone, Ireland manufacturing facility to Novo Nordisk for $92.5 million. The deal is part of Alkermes' strategy to become a pure-play neuroscience company and is expected to close in mid-2024, subject to closing conditions. Post-transaction, Novo Nordisk plans to welcome approximately 400 employees from Alkermes, enhancing its manufacturing capacity for oral products. Alkermes aims to drive operational efficiencies and continued profitability through this sale and retain royalty revenues from products manufactured at the facility.
Read more →ALKSAlkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in...
Alkermes plc has announced a definitive agreement to sell its Athlone, Ireland facility to Novo Nordisk for $92.5 million. The transaction aims to enhance Alkermes' operational efficiencies and profitability as it transitions to a pure-play neuroscience company. The deal is expected to close in mid-2024, pending certain conditions, and will involve subcontracting arrangements to maintain operations temporarily.
Read more →ALKSAlkermes Completes Separation of Oncology Business Alkermes plc (Nasdaq: ALKS) today announced that it has completed the separation of its oncology business into Mural Oncology plc (Mural Oncology), a ...
Alkermes plc has successfully completed the separation of its oncology business, creating Mural Oncology plc, which will trade independently. This strategic move positions Alkermes as a pure-play neuroscience company, enhancing its focus on developing treatments for psychiatric and neurological disorders. The company has also revised its financial expectations for 2023, anticipating increased profitability.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 301 325 3803 Alkermes Completes Separation of Oncology Business — Alkermes Emerges as Pure-Play, Profitable Neuroscience Com
Alkermes plc has completed its separation from its oncology business, now operating as a pure-play neuroscience company with a profitable outlook. The new entity, Mural Oncology plc, will begin trading on Nasdaq under the symbol MURA. The separation is expected to yield significant cost savings and improved financial performance for Alkermes, including updated net income projections for 2023. With this strategic shift, Alkermes aims to capitalize on its proprietary products and pipeline opportunities in the neuroscience sector.
Read more →ALKSAlkermes to Participate in the Jefferies London Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on...
Alkermes plc announced its participation in the Jefferies London Healthcare Conference, scheduled for November 14, 2023. Management will engage in a fireside chat, which will be available via live webcast. The event underscores Alkermes' commitment to investor relations and transparency.
Read more →ALKSAlkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural...
Alkermes plc announced that the SEC has declared effective the Registration Statement on Form 10 for Mural Oncology, marking the planned separation of its oncology business. This separation will create Mural Oncology as an independent, publicly traded company, with shares distributed to Alkermes shareholders. The separation is set to be completed on November 15, 2023.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement DUBLIN
Alkermes plc has announced the effectiveness of Mural Oncology's Form 10 Registration Statement by the U.S. SEC, marking a major step towards the planned separation of its oncology business. This separation will result in Mural Oncology becoming a new, independent, publicly traded company on November 15, 2023. Alkermes shareholders will receive Mural Oncology shares with no action required on their part. While the separation presents new opportunities, it is also subject to certain conditions and risks that could affect its completion.
Read more →ALKS▼ -7.4%on this news
Alkermes plc Reports Third Quarter 2023 Financial Results Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2023. "With solid performance across our proprietary commercial ...
Alkermes plc reported strong financial results for Q3 2023, with revenues of $380.9 million and a 16% increase in net sales of proprietary products. The company anticipates completing the separation of its oncology business by November 2023. Additionally, positive initial data for ALKS 2680, an investigational treatment for narcolepsy, was presented at the World Sleep Congress.
Read more →ALKS▼ -7.4%on this news
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2023 Financial Results — Third Quarter Revenues of $380.9 Million; Net Sales
Alkermes plc has reported a strong financial performance for the third quarter of 2023, achieving revenues of $380.9 million and a net income of $47.8 million. The company indicated a 16% increase in net sales of proprietary products year-over-year, emphasizing the successful settlement of VIVITROL patent litigation as a positive milestone. Additionally, Alkermes plans to separate its oncology business into a new independent entity, Mural Oncology, expected to be completed in November 2023. The ongoing focus on evolving into a neuroscience company appears to position Alkermes for future growth and profitability.
Read more →ALKS▼ -9.6%on this newsshared move
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680,...
Alkermes plc presented preliminary data from a Phase 1 study of ALKS 2680, an orexin 2 receptor agonist for narcolepsy, at the World Sleep Congress. The study showed significant improvements in sleep latency compared to placebo, with ALKS 2680 being well tolerated. The findings support further evaluation in a planned Phase 2 study.
Read more →ALKS▼ -9.6%on this newsshared move
Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy, +1 781 609 6419 Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress — I
Alkermes plc has revealed preliminary results from its Phase 1 study of ALKS 2680, an investigational orexin 2 receptor agonist aimed at treating narcolepsy. Initial findings show dose-dependent improvements in sleep latency in narcolepsy type 1 patients, with the highest dose demonstrating an 18 to 37 minute reduction in sleep latency compared to placebo. The drug was generally well tolerated across all doses, although mild adverse events were noted, particularly at the maximum dose. These findings support further development as the company prepares to advance to Phase 2 studies in 2024.
Read more →ALKSAlkermes to Report Third Quarter Financial Results on October 25, 2023 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Oct. 25, 2023 to...
Alkermes plc will host a conference call on October 25, 2023, to discuss its third quarter financial results and present initial clinical data for ALKS 2680, an investigational drug for narcolepsy. The event will be accessible via webcast and phone, with a replay available afterward. Alkermes continues to develop innovative treatments in neuroscience and oncology.
Read more →ALKSAlkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company's novel, investigational orexin 2 receptor...
Alkermes plc announced it will present initial clinical data for ALKS 2680, an investigational orexin 2 receptor agonist, at the World Sleep Congress from October 20-25, 2023. The data will include findings from a phase 1 study involving patients with narcolepsy type 1. Additionally, preclinical results and qualitative interviews regarding narcolepsy symptoms will also be presented.
Read more →ALKSMural Oncology to Host Investor Webcast on October 17 Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural...
Mural Oncology plc, a new oncology company from Alkermes, will host an investor webcast on October 17, 2023. The event will feature an overview of the company's pipeline, including the investigational immunotherapy nemvaleukin alfa. The separation of Alkermes' oncology business is expected to finalize in Q4 2023, pending certain conditions.
Read more →ALKSAlkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych...
Alkermes plc presented multiple posters at the 36th Annual Psych Congress, showcasing real-world and clinical data focused on serious mental illnesses, addiction, and narcolepsy. Key highlights included the first real-world data assessment of healthcare resource use in patients with schizophrenia or bipolar I disorder and findings from various studies on LYBALVI and ARISTADA. The presentations emphasize Alkermes' ongoing commitment to improving patient care and understanding chronic diseases.
Read more →ALKSAlkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on...
Alkermes plc has announced the launch of its 6th Annual Alkermes Pathways Research Awards program, which will accept applications from September 15 to November 30, 2023. The program aims to support early-career researchers focused on advancing understanding of schizophrenia and bipolar disorder. Grants of up to $100,000 will be awarded to eligible applicants, with a total of approximately $2.3 million provided since the program's inception in 2018.
Read more →ALKSAlkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program Alkermes plc (Nasdaq: ALKS) today announced the recipients of the 2023 Alkermes Inspiration Grants® program. Grants were awarded to 11 nonprofit...
Alkermes plc has announced the recipients of its 2023 Inspiration Grants, awarding funding to 11 nonprofit organizations focused on supporting individuals with addiction, serious mental illness, or cancer. The grants aim to address unmet needs in historically under-resourced communities. Alkermes emphasizes the importance of comprehensive care that includes innovative educational approaches.
Read more →ALKS▲ +7.1%on this newsshared move
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Marisa Borgasano +1 781 609 6659 Alkermes Announces Settlement With Teva Related to VIVITROL Patent Litigation — Company Grants Teva a Lice
Alkermes has reached a settlement with Teva Pharmaceuticals to resolve patent litigation concerning VIVITROL. Under the agreement, Teva will be permitted to market a generic version of VIVITROL starting January 15, 2027, or earlier under specific conditions. The settlement follows a lengthy legal dispute that began in September 2020 when Alkermes initiated litigation over Teva's application for a generic version of the drug. Additional details have not been shared, and the agreement will undergo review by the Federal Trade Commission and Department of Justice.
Read more →ALKS▲ +7.1%on this newsshared move
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to...
Alkermes plc has reached a settlement with Teva Pharmaceuticals regarding patent litigation for VIVITROL. Under the agreement, Teva will be allowed to market a generic version of VIVITROL starting January 15, 2027. The settlement aims to resolve ongoing legal disputes and will be submitted for review to regulatory authorities.
Read more →ALKSale Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2023 Financial Results — Second Quarter Revenues of $617.4 Million Refl
Alkermes plc announced its financial results for the second quarter of 2023, reporting revenues of $617.4 million, driven by strong sales of proprietary products and the reinstatement of INVEGA product royalties. The company also highlighted a successful arbitration with Janssen, leading to $248.4 million in back royalties. Net income for the quarter was $237.1 million, a significant increase from the previous year's loss. Alkermes reiterated its positive financial expectations for the full year and is making progress on separating its oncology business into an independent entity.
Read more →ALKSAlkermes plc Reports Second Quarter 2023 Financial Results Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2023....
Alkermes plc reported strong financial results for Q2 2023, with revenues of $617.4 million, driven by a 21% increase in proprietary product sales. The company successfully concluded arbitration with Janssen, securing $248.4 million in back royalties. Alkermes reiterated its financial expectations for the year, highlighting its solid cash position and ongoing business strategies.
Read more →ALKSAlkermes to Report Second Quarter Financial Results on July 26, 2023 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 26, 2023 to...
Alkermes plc will hold a conference call on July 26, 2023, to discuss its second quarter financial results. The event will be accessible via webcast and phone for both U.S. and international callers. A replay will be available shortly after the event. Alkermes is focused on developing medicines for various neurological and oncological conditions.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 249 8927 Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations 
Alkermes has announced a favorable final award in its arbitration with Janssen Pharmaceutica, resulting in increased 2023 financial expectations by approximately $425 million. This includes back royalties of $194 million for the U.S. sales of certain long-acting products. The final award clarifies future royalty revenues from Janssen, enhancing Alkermes' financial profile and profitability targets. A conference call is scheduled for today to discuss these developments further.
Read more →ALKSAlkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process DUBLIN
Alkermes plc has filed its preliminary proxy statement ahead of its Annual General Meeting, outlining the ongoing director nomination process and its relationship with the investment firm Sarissa. The Board is noted for its recent refreshment, boasting significant industry expertise and diversity. However, tensions remain with Sarissa, which has nominated candidates that the Board has chosen not to endorse. The company seeks to maintain open communication to avoid a contested election.
Read more →ALKS▼ -7%on this news
alex Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2023 Financial Results - First Quarter Revenues of $287.6 Million Reflect Stro
Alkermes plc announced its first quarter financial results for 2023, reporting revenues of $287.6 million, driven by strong sales of proprietary products. The company reaffirmed its financial expectations for the year and highlighted progress in several strategic initiatives, including the planned separation of its oncology business. Key developments include an interim award in an arbitration with Janssen and advancements in the clinical development of ALKS 2680. Despite a GAAP loss per share, Alkermes remains optimistic about its strategic priorities and growth opportunities.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce , +1 781 249 8927 Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration DUBLIN
Alkermes plc has announced the receipt of a second interim award in its ongoing arbitration with Janssen Pharmaceutica. The tribunal has instructed both parties to discuss interest rates and any remaining issues within the next 21 days. This follows a previous interim award that established conditions under which Janssen could not sell developed products without paying royalties. The arbitration could potentially result in additional royalties for Alkermes, although the outcome remains uncertain.
Read more →ALKSalex Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended
Alkermes plc reported its financial results for the year ending December 31, 2022, highlighting a significant revenue of $1.11 billion. The company achieved notable sales of $96 million for LYBALVI in its first year, alongside continued revenue growth for its other products. Looking ahead, Alkermes aims to separate its oncology business to further enhance profitability and has forecasted financial expectations for 2023 that indicate continued growth, despite anticipated net losses. The company remains committed to advancing its neuroscience and oncology projects as part of its strategic initiatives.
Read more →ALKSForward-Looking Statements Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but
Alkermes presented forward-looking statements during the J.P. Morgan Healthcare Conference, outlining expectations for future financial performance and operational plans. Key strategies involve separating its neuroscience and oncology divisions to enhance value, alongside the launch of LYBALVI, a novel treatment for schizophrenia and bipolar disorder. The company also highlights ongoing development activities, including the orexin 2 receptor agonist program and ALKS 2680. However, risks remain, particularly concerning timelines and market conditions impacted by COVID-19.
Read more →ALKSStrategic Growth, IRA Drive Alkermes to Consider Spin-Out of Oncology Business
Alkermes is considering a spin-out of its oncology business to create two independent companies, one focusing on neuroscience and the other on oncology. This move aims to enhance strategic focus and operational flexibility. The oncology division will center on the promising immunotherapy drug nemvaleukin, which is advancing in clinical trials. The separation is influenced by the Inflation Reduction Act's impact on drug pricing.
Read more →ALKSale Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2022 Financial Results — Third Quarter Revenues of $252.4 Million Reflec
ale Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2022 Financial Results Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Prod
Read more →ALKSTips for Managing a Multigenerational, Post-Pandemic Workforce
The article discusses managing a multigenerational workforce in the life sciences industry, emphasizing the importance of understanding individual employee needs over generational stereotypes. It highlights the shift towards flexible work arrangements and the necessity of adapting communication styles to bridge generational gaps. The focus is on fostering diversity, inclusion, and creating a supportive work environment for all employees.
Read more →ALKS▼ -5.3%on this news
alex Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2022 Financial Results - Second Quarter Revenues of $276.2 Million Reflect St
alex Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2022 Financial Results - Second Quarter Revenues of $276.2 Million Reflect Strong Growth in Proprietary Net Sales - - GAAP Loss
Read more →ALKSAlkermes Announces Results of Annual General Meeting of Shareholders All Board Nominees Overwhelmingly Elected by Shareholders DUBLIN
Alkermes Announces Results of Annual General Meeting of Shareholders All Board Nominees Overwhelmingly Elected by Shareholders DUBLIN, July 7, 2022 - Alkermes plc (Nasdaq: ALKS) today announced the results of its 2022 Annual General Meeting of Shareholders (the "Annual Meeting"
Read more →ALKSAlkermes Plants Oncology Flag at ASCO 22
Alkermes showcased its oncology capabilities at ASCO 22, presenting data from the ARTISTRY-1 trial for nemvaleukin alfa, an investigational immunotherapy. The trial demonstrated significant anti-tumor activity in patients with mucosal melanoma and renal cell carcinoma. Alkermes is advancing its oncology pipeline with additional studies, including ARTISTRY-7 and ARTISTRY-3, while emphasizing the importance of patient outcomes.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 249 8927 Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to i
For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 249 8927 Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors - Appoints Nancy J. Wysenski as New Lead Independent D
Read more →ALKS▲ +11.9%on this news
alex Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2022 Financial Results - First Quarter Revenues of $278.5 Million Reflect Stro
alex Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2022 Financial Results - First Quarter Revenues of $278.5 Million Reflect Strong Performance of LYBALVI , ARISTADA and VIVITROL -
Read more →ALKSEarly Career Shift Serendipitous for Kinaset CEO Robert Clarke, Asthma Patients
Kinaset Therapeutics, led by CEO Robert Clarke, is conducting clinical trials for KN-002, an inhaled pan-JAK inhibitor aimed at treating severe asthma. Clarke's career shift from environmental health to respiratory medicine has been crucial in bringing this therapy to patients. The company has completed the first part of a Phase Ib study and is currently dosing asthma patients, with results expected soon.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 249 8927 Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors DUBLIN
Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 249 8927 Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors DUBLIN, Nov. 19, 2021 - Alkermes plc (Nasdaq: ALKS) today announced the appoint
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 249 8927 Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica Investor Conference Call Sch
Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 249 8927 Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica Investor Conference Call Scheduled for Today at 5:00 p.m. ET DUBLIN, Nov. 8, 20
Read more →ALKS▼ -9.1%on this news
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2021 Financial Results - Third Quarter Revenues of $294.1 Million Reflect 11% Growt
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2021 Financial Results - Third Quarter Revenues of $294.1 Million Reflect 11% Growth Year-Over-Year - - Diluted GAAP Loss per Share of $
Read more →ALKS▲ +6.8%on this news
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2021 Financial Results - Second Quarter Revenues of $303.7 Million Reflect 23% Gro
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2021 Financial Results - Second Quarter Revenues of $303.7 Million Reflect 23% Growth Year-Over-Year - - Diluted GAAP Earnings per Shar
Read more →ALKSBioSpace’s Latest Clinical Report Highlights Successes and Failures in 2Q2021
The second quarter of 2021 saw significant activity in the biopharma sector, with over 55 drug candidates approved for clinical studies by the FDA. Notable approvals included Moleac's MLC1501 for traumatic brain injury and Seres Therapeutics' SER-155 for antibiotic-resistant infections. However, several COVID-19 related programs were halted, including those from Roche and Merck, highlighting the challenges in the clinical landscape. Despite setbacks, the quarter also featured 13 novel drug approvals, including Biogen's controversial Alzheimer’s drug, Aduhelm.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Marisa Borgasano, +1 781 609 6659 Alkermes Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder - New Oral
For Investors: Sandy Coombs, +1 781 609 6377 For Media: Marisa Borgasano, +1 781 609 6659 Alkermes Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder - New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Les
Read more →ALKSAfter CRL, Alkermes Wins FDA Approval for Schizophrenia Drug Lybalvi
Alkermes has received FDA approval for its schizophrenia and bipolar I disorder drug, Lybalvi (ALKS 3831). This once-daily oral antipsychotic aims to provide a new treatment option while addressing weight gain concerns associated with similar medications. The approval follows successful clinical trials demonstrating its efficacy and safety, despite previous manufacturing challenges.
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors DUBLIN
For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors DUBLIN, May 20, 2021 Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes Announces Agreement with Sarissa Capital Grants Sarissa Right to Designate Director to Alkermes Board DUBLIN
Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes Announces Agreement with Sarissa Capital Grants Sarissa Right to Designate Director to Alkermes Board DUBLIN, April 30, 2021 Alkermes plc (Nasdaq: ALKS) today announced that it has reached
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2021 Financial Results -First Quarter Revenues of $251.4 Million Reflect Solid Perf
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2021 Financial Results -First Quarter Revenues of $251.4 Million Reflect Solid Performance of VIVITROL and ARISTADA - -Achieves GAAP Los
Read more →ALKSForward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act o
March 25, 2021 Alkermes Investor Day Exhibit 99.1 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, a
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 609 6806 Alkermes Announces Updates to Executive Leadership Team - Blair C. Jackson Appointed Chief Operating Officer and Iai
For Investors: Sandy Coombs, +1 781 609 6377 For Media: Katie Joyce, +1 781 609 6806 Alkermes Announces Updates to Executive Leadership Team DUBLIN, Jan. 6, 2021 - Alkermes plc (Nasdaq: ALKS), a fully integrated, global biopharmaceutical company developing innovative medicines
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 609 6806 Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment - Commits to Non-GAAP Net Income M
For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 609 6806 Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment DUBLIN, Ireland, Dec. 10, 2020 - Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Eva Stroynowski, +1 781 609 6823 Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review - No Clinical E
For Investors: Sandy Coombs, +1 781 609 6377 For Media: Eva Stroynowski, +1 781 609 6823 Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review - No Clinical Efficacy or Safety Issues Raised and No Further Studies Required by FDA to Su
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations - Company Reports Thi
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations - Company Reports Third Quarter Revenues of $265.0 Million, GAAP Net Loss
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs , +1 781 609 6377 For Media: Marisa Borgasano, +1 781 609 6659 FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
For Investors: Sandy Coombs, +1 781 609 6377 For Media: Marisa Borgasano, +1 781 609 6659 FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder DUBLIN, Ireland, Oct. 9, 2020 - Alkermes plc (Nasdaq: ALKS) today announced
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations - Company Reports Se
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations - Company Reports Second Quarter Revenues of $247.5 Million, GAAP Net Los
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update - First Qu
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update - First Quarter Revenues of $246.2 Million, Primarily Driven by
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019, and Provides Financial Expectations for 2020 - Revenues of $1.17 Billion in
Read more →ALKSth Annual J.P. Morgan Healthcare Conference
Shaping the Future of the Business Richard Pops Chief Executive Officer Exhibit 99.1 38th Annual J.P. Morgan Healthcare Conference January 15, 2020 Forward-Looking Statements Certain statements set forth in this presentation constitute "forward-looking statements" within the mea
Read more →ALKSAlkermes Contacts : For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Alkermes Completes Acquisition of Rodin Therapeutics - Acquisition Expands Alkermes' Research and Development Eff
Alkermes Contacts : For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Alkermes Completes Acquisition of Rodin Therapeutics - Acquisition Expands Alkermes' Research and Development Efforts to Include Small Molecule Therapeutics for Synapt
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Rodin Therapeutics Contacts: For Media: Stephanie Simon +1 617 581 9333 Alkermes to Acquire Rodin Therapeutics - A
For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Rodin Therapeutics Contacts: For Media: Stephanie Simon +1 617 581 9333 Alkermes to Acquire Rodin Therapeutics - Acquisition to Expand Alkermes' Presence in CNS to a Wide Range of Neurodeg
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy, +1 781 609 6419 Biogen Contacts: For Media: David Caouette, + 617 679 4945, public.affairs@biogen.com For Investors: Joe Mara, +
For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy, +1 781 609 6419 For Media: David Caouette, + 617 679 4945, public.affairs@biogen.com For Investors: Joe Mara, +1 781 464 2442, IR@biogen.com Biogen and Alkermes Announce FDA Approval of VUMERITY (diroxim
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring - Third Quarter Reve
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Eva Stroynowski +1 781 609 6823 Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring - Third Quarter Revenues of $255.2 Million, Primarily Driven by Approximat
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Matthew Henson +1 781 609 6637 Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retire
For Investors:Sandy Coombs +1 781 609 6377 For Media: Matthew Henson +1 781 609 6637 Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D. DUBLIN, Ireland, Sept. 13, 2019 - Alkermes
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Biogen Contacts: For Investors: Joe Mara, +1 781 464 2442, IR@biogen.com For Media: David Caouette, + 617 679 4945
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Biogen Contacts: For Investors: Joe Mara, +1 781 464 2442, IR@biogen.com For Media: David Caouette, + 617 679 4945, public.affairs@biogen.com Diroximel Fumarate Demo
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Matthew Henson +1 781 609 6637 Alkermes Plc Reports Second Quarter 2019 Financial Results - Second Quarter Revenues of $279.9 Million, Primarily D
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Matthew Henson +1 781 609 6637 Alkermes Plc Reports Second Quarter 2019 Financial Results - Second Quarter Revenues of $279.9 Million, Primarily Driven by Approximately 24% Year-Over-Year Growth of Pr
Read more →ALKSAlkermes Contacts : For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder - Followin
Alkermes Contacts : For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder - Following Pre-NDA Meeting With FDA, Company Plans to Submit N
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Matthew Henson +1 781 609 6637 Alkermes Plc Reports First Quarter 2019 Financial Results - First Quarter Revenues of $223.1 Million, Primarily Dri
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Matthew Henson +1 781 609 6637 Alkermes Plc Reports First Quarter 2019 Financial Results - First Quarter Revenues of $223.1 Million, Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Produc
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Matthew Henson, +1 781 609 6637 Alkermes Announces Departure of Jim Robinson
Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Matthew Henson, +1 781 609 6637 Alkermes Announces Departure of Jim Robinson DUBLIN, Ireland, April 8, 2019 Alkermes plc (Nasdaq: ALKS) announced today that Jim Robinson, President and Chief Operati
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Matthew Henson +1 781 609 6637 Alkermes Plc Reports Financial Results for the Year Ended
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Matthew Henson +1 781 609 6637 Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019 - Record Revenues of $1.09 Billion in 2018, Driven b
Read more →ALKSAlkermes Contacts : For Investors: Sandy Coombs +1 781 609 6377 For Media: Sherry Feldberg +1 781 609 6276 Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Applicat
Alkermes Contacts : For Investors: Sandy Coombs +1 781 609 6377 For Media: Sherry Feldberg +1 781 609 6276 Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application DUBLIN, Ireland, Feb. 1, 2019 - Alkermes plc (Nasd
Read more →ALKSAlkermes Contacts: For Investors: Eva Stroynowski +1 781 609 6823 Sandy Coombs +1 781 609 6377 For Media: Sherry Feldberg +1 781 609 6276 Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS
Alkermes Contacts: For Investors: Eva Stroynowski +1 781 609 6823 Sandy Coombs +1 781 609 6377 For Media: Sherry Feldberg +1 781 609 6276 Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia Co-Primary Endpoin
Read more →ALKSAlkermes Contacts: For Investors: Eva Stroynowski +1 781 609 6823 Sandy Coombs +1 781 609 6377 For Media: Sherry Feldberg +1 781 609 6276 Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the
Alkermes Contacts: For Investors: Eva Stroynowski +1 781 609 6823 Sandy Coombs +1 781 609 6377 For Media: Sherry Feldberg +1 781 609 6276 Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder D
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Sherry Feldberg +1 781 609 6276 Alkermes Plc Reports Third Quarter 2018 Financial Results - Third Quarter Revenues
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Sherry Feldberg +1 781 609 6276 Alkermes Plc Reports Third Quarter 2018 Financial Results - Third Quarter Revenues Increased to $248.7 Million, Driven by 24% Year-Ove
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 Alkermes Plc Reports Second Quarter 2018 Financial Results — Second Quarter
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 Alkermes Plc Reports Second Quarter 2018 Financial Results Second Quarter Revenues Increase to $304.6 Million, Driven by License Reven
Read more →ALKSAlkermes Contacts: For Investors: Eva Stroynowski +1 781 609 6823 Sandy Coombs +1 781 609 6377 For Media: Marisa Borgasano +1 781 609 6659 FDA Approves ARISTADA INITIO ™ for the Initiation of ARISTADA ® for S
Alkermes Contacts: For Investors: Eva Stroynowski +1 781 609 6823 Sandy Coombs +1 781 609 6377 For Media: Marisa Borgasano +1 781 609 6659 FDA Approves ARISTADA INITIO for the Initiation of ARISTADA for Schizophrenia Novel Regimen Enables Physicians to Fully Dose Up to Tw
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 Alkermes Plc Reports First Quarter 2018 Financial Results First Quarter Revenues I
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 Alkermes Plc Reports First Quarter 2018 Financial Results First Quarter Revenues Increase to $225.2 Million, Primarily Driven by 20% Ye
Read more →ALKSAlkermes Contacts: For Investors: Eva Stroynowski, +1 781 609 6823 Sandy Coombs, +1 781 609 6377 For Media: Jennifer Snyder, +1 781 609 6166 Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5
Alkermes Contacts: For Investors: Eva Stroynowski, +1 781 609 6823 Sandy Coombs, +1 781 609 6377 For Media: Jennifer Snyder, +1 781 609 6166 Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive D
Read more →ALKSAlkermes Contacts: For Investors: Eva Stroynowski, +1 781 609 6823 Sandy Coombs, +1 781 609 6377 For Media: Jennifer Snyder, +1 781 609 6166 Alkermes Receives Refusal to File Letter From FDA for ALKS 5461 Conference Call
Alkermes Contacts: For Investors: Eva Stroynowski, +1 781 609 6823 Sandy Coombs, +1 781 609 6377 For Media: Jennifer Snyder, +1 781 609 6166 Alkermes Receives Refusal to File Letter From FDA for ALKS 5461 Conference Call Scheduled for Today at 8:30 a.m. ET DUBLIN, Ireland
Read more →ALKSAlkermes Contacts: For Investors: Eva Stroynowski +1 781 609 6823 Sandy Coombs +1 781 609 6377 For Media: Jennifer Snyder +1 781 609 6166 Alkermes Appoints James Robinson as President and Chief Operating Officer
Alkermes Contacts: For Investors: Eva Stroynowski +1 781 609 6823 Sandy Coombs +1 781 609 6377 For Media: Jennifer Snyder +1 781 609 6166 Alkermes Appoints James Robinson as President and Chief Operating Officer DUBLIN, Ireland, March 1, 2018 Alkermes plc (Nasdaq: ALKS) t
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 Alkermes Appoints Shane Cooke to Board of Directors
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 Alkermes Appoints Shane Cooke to Board of Directors DUBLIN, Ireland, Feb. 14, 2018 Alkermes plc (NASDAQ: ALKS) today announced the app
Read more →ALKSRelevant slides from Alkermes plc's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on
Relevant slides from Alkermes plc's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on January 9, 2018:
Read more →ALKSBiogen Contacts: For Investors: Matt Calistri +1 781 464 2442 For Media: Matt Fearer +1 781 464 3260 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyd
Biogen Contacts: For Investors: Matt Calistri +1 781 464 2442 For Media: Matt Fearer +1 781 464 3260 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 BIOGEN AND ALKERMES ANNOUNCE L
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 ALKERMES PLC REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS — Third Quarter T
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 ALKERMES PLC REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Third Quarter Total Revenues Increased 21% Year-Over-Year to $217.4 Million,
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 ALKERMES PLC REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS — Second Quarter
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 ALKERMES PLC REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Second Quarter Revenues Increased 12% Year-Over-Year to $218.8 Million, GAA
Read more →ALKSAlkermes Contacts: For Investors: Eva Stroynowski +1 781-609-6823 Sandy Coombs +1 781-609-6377 For Media: Jennifer Snyder +1 781-609-6166 ALKERMES ANNOUNCES POSITIVE PRELIMINARY TOPLINE RESULTS FROM PHASE 3 ANTIPSYCHOTIC
Alkermes Contacts: For Investors: Eva Stroynowski +1 781-609-6823 Sandy Coombs +1 781-609-6377 For Media: Jennifer Snyder +1 781-609-6166 ALKERMES ANNOUNCES POSITIVE PRELIMINARY TOPLINE RESULTS FROM PHASE 3 ANTIPSYCHOTIC EFFICACY STUDY OF ALKS 3831 FOR TREATMENT OF SCHIZ
Read more →ALKSAlkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 ALKERMES PLC REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS — First Quarter R
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 Eva Stroynowski +1 781 609 6823 For Media: Jennifer Snyder +1 781 609 6166 ALKERMES PLC REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS First Quarter Revenues Increased 22% Year-Over-Year to $191.8 Million, GAAP
Read more →Competitive Position
How ALKS ranks across every disease it competes inCompetitive Position is a premium feature
See how ALKS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial